1. Home
  2. AFMD vs SPHL Comparison

AFMD vs SPHL Comparison

Compare AFMD & SPHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AFMD
  • SPHL
  • Stock Information
  • Founded
  • AFMD 2000
  • SPHL 2002
  • Country
  • AFMD Germany
  • SPHL Singapore
  • Employees
  • AFMD N/A
  • SPHL N/A
  • Industry
  • AFMD Biotechnology: Pharmaceutical Preparations
  • SPHL Homebuilding
  • Sector
  • AFMD Health Care
  • SPHL Consumer Discretionary
  • Exchange
  • AFMD Nasdaq
  • SPHL Nasdaq
  • Market Cap
  • AFMD 55.6M
  • SPHL 53.7M
  • IPO Year
  • AFMD 2014
  • SPHL 2024
  • Fundamental
  • Price
  • AFMD $3.65
  • SPHL $4.50
  • Analyst Decision
  • AFMD Strong Buy
  • SPHL
  • Analyst Count
  • AFMD 5
  • SPHL 0
  • Target Price
  • AFMD $16.25
  • SPHL N/A
  • AVG Volume (30 Days)
  • AFMD 98.0K
  • SPHL 149.9K
  • Earning Date
  • AFMD 11-14-2024
  • SPHL 11-25-2024
  • Dividend Yield
  • AFMD N/A
  • SPHL N/A
  • EPS Growth
  • AFMD N/A
  • SPHL 413.11
  • EPS
  • AFMD N/A
  • SPHL 0.09
  • Revenue
  • AFMD $7,959,927.00
  • SPHL $11,020,429.00
  • Revenue This Year
  • AFMD N/A
  • SPHL N/A
  • Revenue Next Year
  • AFMD $48.98
  • SPHL N/A
  • P/E Ratio
  • AFMD N/A
  • SPHL $48.58
  • Revenue Growth
  • AFMD N/A
  • SPHL 112.84
  • 52 Week Low
  • AFMD $2.92
  • SPHL $3.82
  • 52 Week High
  • AFMD $8.95
  • SPHL $4.90
  • Technical
  • Relative Strength Index (RSI)
  • AFMD 55.19
  • SPHL N/A
  • Support Level
  • AFMD $3.63
  • SPHL N/A
  • Resistance Level
  • AFMD $3.98
  • SPHL N/A
  • Average True Range (ATR)
  • AFMD 0.24
  • SPHL 0.00
  • MACD
  • AFMD 0.04
  • SPHL 0.00
  • Stochastic Oscillator
  • AFMD 55.65
  • SPHL 0.00

About AFMD Affimed N.V.

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.

About SPHL Springview Holdings Ltd Class A Ordinary Shares

Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation.

Share on Social Networks: